Introduction:
Brazil is one of the fastest-growing pharmaceutical markets
in the world and has an expanding population of type 2 diabetes patients. The
growth of the diagnosed and drug-treated patient populations, increased use of
new-generation antidiabetics, and the launch of several novel agents will
further contribute to the market’s growth. Overall, multinational corporations,
which were responsible for 80% of sales for type 2 diabetes in 2008, will
continue to dominate the market. Brazil’s type 2 diabetes therapy market
already exceeds the size of Italy’s market and will exceed that of the United
Kingdom, becoming one of the largest pharmaceutical markets for type 2 diabetes
in the world within five years.
Questions Answered in This Report:
*
The size and the growth rate of the aging population in Brazil
are key drivers of the pharmaceutical market for chronic diseases.
What
factors are driving the rise of type 2 diabetes cases in Brazil? What
percentage of these patients will be diagnosed and drug-treated through 2013?
*
Brazilian physicians prescribe antidiabetic agents based on the
efficacy and safety profiles of individual drugs.
What other factors
influence Brazilian physicians’ prescribing habits? How do physicians choose
between a Western-branded drug and a Brazilian-manufactured equivalent for the
treatment of type 2 diabetes? What are physicians’ opinions of antidiabetic
therapies currently on the market?
*
The type 2 diabetes market in Brazil is growing rapidly,
characterized by strong double-digit annual sales growth.
What was the size
of the type 2 diabetes market in 2008? What are the key opportunities
for growth in the type 2 diabetes market? Which agents, current and emerging,
will be the key drivers of market growth during the forecast period? Which
drugs will dominate the Brazilian type 2 diabetes market in 2013?Scope:
Market covered: Brazil
Primary research: 100 physicians (40 general
practitioners and 60 endocrinologists) surveyed in São Paulo, Rio de Janeiro,
Belo Horizonte, and Brasilia; separate in-depth interviews with 10 Brazilian
physicians.
Epidemiology: We provide the number of prevalent cases
of type 2 diabetes in Brazil and in four major cities over a ten-year period
(2008-2018). We also estimate diagnosis and drug-treatment rates among the
prevalent population in 2008 and 2013.
Market forecast features: We include a detailed forecast
for 13 type 2 diabetes drug classes and leading products from 2008 to 2013,
using a combination of historical trend analysis and an epidemiology-based,
bottom-up market model.